Satoshi Noda1, Takashi Otsuji2, Masato Baba3, Tetsuya Yoshida3, Susumu Kageyama3, Keisei Okamoto3, Yusaku Okada3, Akihiro Kawauchi3, Hiroyuki Onishi4, Daiki Hira1, Shin-Ya Morita1, Tomohiro Terada5. 1. Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan. 2. Department of Pharmacy, Shiga Medical Center for Adults, Shiga, Japan. 3. Department of Urology, Shiga University of Medical Science Hospital, Shiga, Japan. 4. Department of Urology, Shiga Medical Center for Adults, Shiga, Japan. 5. Department of Pharmacy, Shiga University of Medical Science Hospital, Shiga, Japan. Electronic address: teradat@belle.shiga-med.ac.jp.
Abstract
BACKGROUND: Sunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability. PATIENTS AND METHODS: A retrospective, observational clinical study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib concentration in a steady state during the first cycle. RESULTS: The median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of thrombocytopenia, anorexia, and fatigue. Patients with ≥ 100 ng/mL total sunitinib (n = 8), compared with patients with < 100 ng/mL (n = 13), had a greater incidence of Grade ≥ 3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]). Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02). CONCLUSION: Results of this study suggest that therapeutic drug monitoring of sunitinib could be useful for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is ≥ 100 ng/mL, to avoid unnecessary early discontinuation of treatment.
BACKGROUND:Sunitinib has been approved for the treatment of metastatic renal cell carcinoma (RCC). Sunitinib pharmacokinetics shows a large interpatient variability. PATIENTS AND METHODS: A retrospective, observational clinical study of 21 patients with RCC was performed. Sunitinib was administered for 4 weeks of a 6-week cycle for the first cycle. We evaluated the association of sunitinib-induced toxicities and clinical outcomes with the trough total sunitinib concentration in a steady state during the first cycle. RESULTS: The median total sunitinib concentration was 91.8 ng/mL (range, 49.8-205 ng/mL). There was an association between total sunitinib concentration and the severity of thrombocytopenia, anorexia, and fatigue. Patients with ≥ 100 ng/mL total sunitinib (n = 8), compared with patients with < 100 ng/mL (n = 13), had a greater incidence of Grade ≥ 3 toxicities (6 patients [75.0%] vs. 3 patients [23.1%]). Patients with < 100 ng/mL total sunitinib had significantly longer time to treatment failure (TTF) and progression-free survival (PFS) time than patients with ≥ 100 ng/mL (median TTF, 590 vs. 71 days; P = .04; median PFS, 748 vs. 238 days; P = .02). CONCLUSION: Results of this study suggest that therapeutic drug monitoring of sunitinib could be useful for avoiding severe toxicities. Dose reduction might be needed, especially when the total sunitinib concentration is ≥ 100 ng/mL, to avoid unnecessary early discontinuation of treatment.
Authors: Neeltje Steeghs; Alwin D R Huitema; Stefanie L Groenland; Remy B Verheijen; Markus Joerger; Ron H J Mathijssen; Alex Sparreboom; Jos H Beijnen; Jan H Beumer Journal: Clin Cancer Res Date: 2021-09-21 Impact factor: 12.531
Authors: M H Diekstra; A Belaustegui; J J Swen; E Boven; D Castellano; H Gelderblom; R H Mathijssen; J García-Donas; C Rodríguez-Antona; B I Rini; H-J Guchelaar Journal: Pharmacogenomics J Date: 2016-01-26 Impact factor: 3.550
Authors: Guillermo de Velasco; Kathryn P Gray; Lana Hamieh; Yuksel Urun; Hallie A Carol; Andre P Fay; Sabina Signoretti; David J Kwiatkowski; David F McDermott; Matthew Freedman; Mark M Pomerantz; Toni K Choueiri Journal: Eur Urol Focus Date: 2016-04-23